A randomized open-label trial of paroxetine versus paroxetine plus sulpiride in the treatment of major depressive disorder

Depressive Disorder ◽

Open Label ◽

Major Depressive ◽

Effectiveness and acceptability of accelerated repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant major depressive disorder: An open label trial

Journal of Affective Disorders ◽

10.1016/j.jad.2014.10.068 ◽

2015 ◽

Vol 173 ◽

pp. 216-220 ◽

Cited By ~ 48

Author(s):

Alexander McGirr ◽

Frederique Van den Eynde ◽

Santiago Tovar-Perdomo ◽

Marcelo P.A. Fleck ◽

Marcelo T. Berlim

Keyword(s):

Transcranial Magnetic Stimulation ◽

Depressive Disorder ◽

Magnetic Stimulation ◽

Repetitive Transcranial Magnetic Stimulation ◽

Treatment Resistant ◽

Open Label ◽

Major Depressive ◽

P.2.a.005 Dosing of aripiprazole adjunctive therapy for Asian patients with major depressive disorder: a 24-week open label trial

European Neuropsychopharmacology ◽

10.1016/s0924-977x(11)70569-7 ◽

2011 ◽

Vol 21 ◽

pp. S356-S357

Author(s):

Y.M. Bai

Keyword(s):

Depressive Disorder ◽

Adjunctive Therapy ◽

Open Label ◽

Major Depressive ◽

Asian Patients ◽

Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial

Depression and Anxiety ◽

10.1002/da.20458 ◽

2008 ◽

Vol 25 (12) ◽

pp. E173-E181 ◽

Cited By ~ 6

Author(s):

Pratap Chokka ◽

Mark Legault

Keyword(s):

Primary Care ◽

Depressive Disorder ◽

Open Label ◽

Major Depressive ◽

Primary Care Settings ◽

Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial

Psychopharmacology ◽

10.1007/s00213-020-05692-9 ◽

2020 ◽

Cited By ~ 1

Author(s):

Richard J. Zeifman ◽

Nikhita Singhal ◽

Rafael G. dos Santos ◽

Rafael F. Sanches ◽

Flávia de Lima Osório ◽

...

Keyword(s):

Recurrent Major Depressive Disorder

Single Dose ◽

Depressive Disorder ◽

Open Label ◽

Major Depressive ◽

Open Label Trial ◽

Translocator Protein Distribution Volume Predicts Reduction of Symptoms During Open-Label Trial of Celecoxib in Major Depressive Disorder

Biological Psychiatry ◽

10.1016/j.biopsych.2020.03.007 ◽

2020 ◽

Vol 88 (8) ◽

pp. 649-656 ◽

Cited By ~ 6

Author(s):

Sophia Attwells ◽

Elaine Setiawan ◽

Pablo M. Rusjan ◽

Cynthia Xu ◽

Celeste Hutton ◽

...

Keyword(s):

Depressive Disorder ◽

Distribution Volume ◽

Translocator Protein ◽

Protein Distribution ◽

Open Label ◽

Major Depressive ◽

An 8-Week, Open-Label Trial of Duloxetine for Comorbid Major Depressive Disorder and Chronic Headache

The Journal of Clinical Psychiatry ◽

10.4088/jcp.v69n0912 ◽

2008 ◽

Vol 69 (9) ◽

pp. 1449-1454 ◽

Cited By ~ 19

Author(s):

Fernando M. Volpe

Keyword(s):

Depressive Disorder ◽

Chronic Headache ◽

Open Label ◽

Major Depressive ◽

Faculty Opinions recommendation of An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727194212.793529706 ◽

2017 ◽

Author(s):

Adam Farmer

Keyword(s):

Irritable Bowel Syndrome ◽

Pilot Study ◽

Depressive Disorder ◽

Open Label ◽

Major Depressive ◽

Irritable Bowel

Zuranolone in Major Depressive Disorder: Interim Safety Results From a Phase 3, Open-Label, Longitudinal Study

Biological Psychiatry ◽

10.1016/j.biopsych.2021.02.413 ◽

2021 ◽

Vol 89 (9) ◽

pp. S161

Author(s):

Andrew Cutler ◽

Scott T. Aaronson ◽

Gregory W. Mattingly ◽

Samuel T. Wilkinson ◽

Robert Lasser ◽

...

Keyword(s):

Longitudinal Study ◽

Depressive Disorder ◽

Open Label ◽

Major Depressive ◽

Phase 3

Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population

Neuropsychiatric Disease and Treatment ◽

10.2147/ndt.s120190 ◽

2017 ◽

Vol Volume 13 ◽

pp. 515-526 ◽

Cited By ~ 5

Author(s):

Kaida Jiang ◽

Lingjiang Li ◽

Wang Xueyi ◽

Maosheng Fang ◽

Jianfei Shi ◽

...

Keyword(s):

Depressive Disorder ◽

Prospective Study ◽

Chinese Population ◽

Anxiety Symptoms ◽

Open Label ◽

Major Depressive

Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial

International Journal of Clinical Practice ◽

10.1111/j.1742-1241.2010.02624.x ◽

2011 ◽

Vol 65 (3) ◽

pp. 323-329 ◽

Cited By ~ 7

Author(s):

J. E. Kim ◽

S. J. Yoon ◽

J. Kim ◽

J. Y. Jung ◽

H. S. Jeong ◽

...

Keyword(s):

Depressive Disorder ◽

Controlled Trial ◽

Anxiety Symptoms ◽

Open Label ◽

Major Depressive